Story thread · 2 reports / 1 sources

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

financialpost.com · 4dShare

Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics […]

First report: Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results — financialpost.com, 6d